Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

NCT01416038 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

BIOLOGICAL: DPX-Survivac
DRUG: low dose cyclophosphamide (oral)

Sponsor

ImmunoVaccine Technologies, Inc. (IMV Inc.)